SightLine Partners

SightLine Partners, established in 2004, is a venture capital firm headquartered in Bloomington, Minnesota, with an additional office in Palo Alto, California. The company specializes in late-stage investments, focusing on medical technology, biotechnology, and healthcare services sectors within the United States. SightLine Partners typically invests between $2 million and $8 million, structuring deals as preferred stock, and aims to exit within five years. The firm's investment strategy is to support emerging growth and later-stage companies, particularly in therapeutic areas such as vascular diseases, diabetes, and nervous system disorders.

Josh Baltzell

Venture Partner

Joe Biller

Managing Director

Andrea Crooks

Vice President of Finance

Kunal Paymaster

Managing Director

Archie Smith

Managing Director

Nicholas Speltz

Associate

22 past transactions

Magnolia Medical Technologies

Venture Round in 2022
Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Magnolia Medical Technologies

Series C in 2019
Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Vapotherm

Series D in 2018
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

EndoGastric Solutions

Series I in 2018
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

EarLens

Series C in 2017
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Monteris Medical

Series C in 2017
Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Vapotherm

Series D in 2017
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Vapotherm

Series C in 2015
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Conventus Orthopaedics

Series A in 2014
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

Conventus Orthopaedics

Venture Round in 2013
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

CVRx

Series F in 2013
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Celleration

Series E in 2011
Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

Anulex Technologies

Series D in 2009
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Broncus Medical

Series G in 2008
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, including emphysema and lung cancer. Based in Mountain View, California, with an international presence in Nyon, Switzerland, Broncus is focused on addressing significant unmet medical needs in interventional pulmonology. The company is exploring its Exhale product line, which features a patented treatment method known as Airway Bypass, aimed at providing a minimally-invasive solution for patients suffering from homogeneous emphysema. Broncus is currently conducting the pivotal EASE Trial, enrolling patients worldwide to evaluate the efficacy of this treatment in severe cases of the disease. Additionally, Broncus offers a range of innovative products designed to enhance diagnostic and therapeutic outcomes in lung care, including the Archimedes System, LungPoint, and InterVapor System.

PHT

Series F in 2008
PHT is a leading provider of electronic patient reported outcome (ePRO) solutions utilized in clinical trials globally. The company offers advanced technologies, including the LogPad and StudyPad systems, which enhance data quality and support efficient data capture and management. PHT's StudyWorks online portal grants study sponsors, monitors, and sites real-time access to critical trial data, facilitating informed decision-making. By partnering with biopharmaceutical and medical device companies, PHT enables more effective and accurate clinical studies, ultimately contributing to the success of trials.

CVRx

Series E in 2008
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Atritech

Series D in 2007
Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

CVRx

Series D in 2007
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

Broncus Medical

Series F in 2006
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, including emphysema and lung cancer. Based in Mountain View, California, with an international presence in Nyon, Switzerland, Broncus is focused on addressing significant unmet medical needs in interventional pulmonology. The company is exploring its Exhale product line, which features a patented treatment method known as Airway Bypass, aimed at providing a minimally-invasive solution for patients suffering from homogeneous emphysema. Broncus is currently conducting the pivotal EASE Trial, enrolling patients worldwide to evaluate the efficacy of this treatment in severe cases of the disease. Additionally, Broncus offers a range of innovative products designed to enhance diagnostic and therapeutic outcomes in lung care, including the Archimedes System, LungPoint, and InterVapor System.

LipoScience

Series F in 2006
LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

Anulex Technologies

Series C in 2006
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Verax Biomedical

Series B in 2005
Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.